Alliance Pharma PLC Hardman Research: Strong Operational Cashflow

TIDMAPH

Alliance Pharma PLC

29 January 2018

Hardman Research: Strong Operational Cashflow

2017: strong operational cashflow - Alliance Pharma is continuing with its buy-and-build strategy having evolved through 35 acquisitions over a period of 20 years into a profitable, cash-generative, specialty pharma business. The company has a mix of international growth brands - notably Kelo-Cote and MacuShield - and a bedrock of solid local low-growth brands. In a trading statement for 2017, strong sales of its international growth brands have underpinned group sales growth and helped generate strong underlying operational cashflow. The recent acquisitions of Vamousse (third international growth brand) and Ametop (bedrock brand) look set to further enhance future performance.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/alliance-pharma-documents/29-01-18-alliance-pharma.pdf

 
 To contact us:          Contacts:       [e-mail] 
  Hardman & Co            Dr Martin       [e-mail] 
  35 New Broad Street     Hall            [e-mail] 
  London                  Dr Dorothea     www.hardmanandco.com 
  EC2M 1NH                Hill 
  Follow us on Twitter    Dr Gregoire 
  @HardmanandCo           Pave 
                          [phone] 
                          7622 
 

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRALLFLLLTIAFIT

(END) Dow Jones Newswires

January 29, 2018 06:20 ET (11:20 GMT)